See the DrugPatentWatch profile for stiripentol

Stiripentol and fenfluramine are both drugs used to treat rare forms of epilepsy. Fenfluramine was previously used as an appetite suppressant but was withdrawn from the market due to safety concerns. However, a new formulation of fenfluramine has been approved for the treatment of Dravet syndrome, a severe form of epilepsy.

Stiripentol is also approved for the treatment of Dravet syndrome, and it has been available for several years. However, its use is limited due to its side effects and drug interactions.

When comparing the cost-effectiveness of stiripentol and fenfluramine, several factors must be considered, including the drug's list price, out-of-pocket costs for patients, and the impact on health outcomes.

According to DrugPatentWatch.com, stiripentol has been off-patent since 2010, which means that generic versions of the drug are available. This can lead to lower costs for patients and the healthcare system. On the other hand, fenfluramine is a newly approved drug, and its list price is likely to be higher than stiripentol.

However, it is essential to consider the impact of these drugs on health outcomes. Fenfluramine has been shown to reduce seizure frequency in patients with Dravet syndrome, and it may have a more significant impact on health outcomes than stiripentol. Therefore, even if fenfluramine has a higher list price, it may be cost-effective if it leads to better health outcomes and reduced healthcare utilization.

In summary, while stiripentol may be less expensive than fenfluramine due to generic availability, the cost-effectiveness of these drugs depends on several factors, including their impact on health outcomes. It is essential to consider these factors when evaluating the cost-effectiveness of these drugs.

Sources:

* DrugPatentWatch.com: Stiripentol (<https://www.drugpatentwatch.com/drugs/stiripentol>)
* DrugPatentWatch.com: Fenfluramine (<https://www.drugpatentwatch.com/drugs/fenfluramine>)
* FDA Approves New Indication for Fenfluramine to Treat Dravet Syndrome (<https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-fenfluramine-treat-dravet-syndrome>)
* Stiripentol for Dravet Syndrome (<https://www.ncbi.nlm.nih.gov/books/NBK535423/>)
* Fenfluramine for Dravet Syndrome (<https://www.ncbi.nlm.nih.gov/books/NBK557800/>)